Positive Data Announced on RSV Vaccine That Benefits Infants

November 8, 2022

In a recent press release, biopharmaceutical company Pfizer announced high efficacy in the phase three trial of its investigational respiratory syncytial virus (RSV) vaccine designed to be administered to expecting mothers for the benefit of their babies at birth and beyond.

Specifically, when looking at severe medically attended lower respiratory tract, the efficacy for the vaccine was 81.8% through the first 90 days of life for newborns. In addition, substantial efficacy of 69.4% was demonstrated for infants over the six-month follow-up period.

“We are thrilled by these data as this is the first-ever investigational vaccine shown to help protect newborns against severe RSV-related respiratory illness immediately at birth,” said Annaliesa Anderson, PhD, Pfizer senior vice president and chief scientific officer, vaccine research and development.

RSV is a common respiratory virus that usually causes mild, cold-like symptoms but can be more serious for infants and older adults. The release noted that hospitals and clinicians in some areas of the United States are currently reporting overcapacity at their facilities due to RSV.

Latest Articles

Examining the Options in Customized Facility Software
November 18, 2026 Connor O’Brien

Examining the Options in Customized Facility Software

November 16, 2026 Ilan Rubinsztein

Plan for Storms on Sunny Days

November 11, 2026 Jeff Cross

A Building Full of Carpet Isn’t Always a Building Full of Profit

Sponsored Articles

Every Breath Counts
November 6, 2026

Every Breath Counts

October 26, 2026

Better Wiping Products Start with Sellars

October 23, 2026

What Is Cleaning Really Costing You?

Recent News

Kim at the ISSA Show North America 2026

From Vision to Action: ISSA Celebrates Progress and People

ISSA Housekeeping Olympics Adds Triathlon in its 36 Year

Joy Mangano Inspires Leaders to Turn Challenges into Opportunities for Growth